A Phase 1/2, Open-Label, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of DT-DEC01 Therapy in Patients with Duchenne Muscular Dystrophy

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Duchenne muscular dystrophy cell therapy Dystrogen Therapeutics (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms DEC for DMD
Sponsors Dystrogen Therapeutics

26 Sep 2022 Results published in a Dystrogen Therapeutics media release.
07 Apr 2022 According to a Dystrogen Therapeutics media release, the Data and Safety Monitoring Board (DSMB) reviewed the low dose (2 million DEC cells per kg) clinical cohort data and gave a positive opinion on the safety of DT-DEC01 therapy. The DSMB recommend initiating the 4M/kg cohort.
07 Apr 2022 According to a Dystrogen Therapeutics media release, this study is conducted in Poland under a hospital exemption protocol of DT-DEC01.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com